Eliminating pharmaceutical rebates: a wild goose chase?

Reducing patient healthcare costs is imperative, write Matthew Majewski (pictured above, on left) and Andrew Parece, vice presidents of Charles River Associates, in a Special Report.

In July, the Trump administration restated its intention to remove rebates for Medicare Part D drugs as one of several new Executive Orders aimed at lowering prescription drug costs. One of the administration's goals in revisiting the rebate elimination plan is to reduce the potential for unintended incentives created by the protection of rebates under the safe-harbor provisions of the Anti-Kickback Statute.